Elarekibep is a Recombinant Protein owned by AstraZeneca, and is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing.
Elarekibep acts by antagonizing interleukin 4 receptor alpha (IL-4RA) and blocks the action of IL-4 and IL-13. IL-4 and IL-13 are the primary cytokines secreted mainly by T helper type 2 (Th2) cells and activate pSTAT6 that helps in regulation of transcription process and is involved in allergic inflammatory diseases. The drug candidate exhibits therapeutic activity by inhibiting IL-4RA induced pSTAT6 mediated signalling and ameliorates the disease condition.
The revenue for Elarekibep is expected to reach a total of $57m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Elarekibep NPV Report.
Elarekibep is under development for the treatment of moderate to severe asthma. The drug candidate is administered through an inhalation and intravenous route. It targets the interleukin-4 receptor alpha (IL4RA). It is based on Anticalin platform technology.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.
Quick View – Elarekibep
|Highest Development Stage|